Thermo Fisher Scientific and NanoPin: Advancing Infectious Disease Detection Technology
Thermo Fisher Scientific and NanoPin Technologies, Inc., the developer of the novel NanoPin diagnostic platform for rapid and quantified results from patient blood samples, have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.
Through the detection of disease-related antigens directly from patient blood samples, NanoPin’s diagnostic platform using Thermo Fisher’s advanced LC-MS technology aims to lead to the development of sensitive clinical assays for infectious disease. This could enable healthcare providers to reduce time to results, determine infection stage and monitor patient response to prescribed treatment. The quantified information gleaned from the combined technology could, therefore, support clinical decision-making and the provision of personalized patient care unique to their disease state.